RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of “Hold” from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $4.00.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of RAPT Therapeutics in a report on Monday, March 10th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its position in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after acquiring an additional 29,195 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock worth $84,000 after buying an additional 42,636 shares in the last quarter. Sei Investments Co. acquired a new stake in RAPT Therapeutics in the 4th quarter valued at approximately $64,000. Renaissance Technologies LLC boosted its position in RAPT Therapeutics by 25.5% during the 4th quarter. Renaissance Technologies LLC now owns 369,736 shares of the company’s stock worth $584,000 after acquiring an additional 75,136 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of RAPT Therapeutics by 1,128.3% during the 4th quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company’s stock worth $324,000 after acquiring an additional 188,461 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Trading Down 0.0 %

Shares of NASDAQ RAPT opened at $0.80 on Friday. The firm has a market capitalization of $105.61 million, a PE ratio of -0.29 and a beta of -0.04. The firm’s 50-day moving average is $1.03 and its 200-day moving average is $1.26. RAPT Therapeutics has a 1 year low of $0.75 and a 1 year high of $6.05.

RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.23. As a group, equities research analysts anticipate that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.